CompletedNCT01143090

Long-Term Safety of Lurasidone After Switching Treatment

About this title

A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder

Medication studyAges 18+United StatesSchizophrenia

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations: Little Rock and 26 more locationsSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateAugust 2010

Recruitment status: Completed
Enrollment listed in the registry: 149
Sponsor: Sumitomo Pharma America, Inc.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States
Age range: Over 18 Years
Official registry ID: NCT01143090
Official title: Show the full official title
A 24-Week, Flexible-Dose, Open-label Extension Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder (Protocol No. D1050290)

Completed

Little Rock · Escondido · Garden Grove

21 more locations

FAQ

Who is behind this study?

The study sponsor is Sumitomo Pharma America, Inc., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Lurasidone HCl.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.